<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="170876">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00872027</url>
  </required_header>
  <id_info>
    <org_study_id>R34MH082156</org_study_id>
    <secondary_id>R34MH082156</secondary_id>
    <secondary_id>DSIR 83 ATP</secondary_id>
    <nct_id>NCT00872027</nct_id>
  </id_info>
  <brief_title>Preventing Depression in People Receiving Mechanical Ventilation in an Intensive Care Unit</brief_title>
  <official_title>Feasibility Study to Prevent Post-ICU Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the effectiveness of antidepressant medication in preventing
      depression and improving recovery in people who have been supported by mechanical
      ventilators in an intensive care unit (ICU).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      More than one third of all people admitted to ICUs in hospitals require mechanical
      ventilation for respiratory failure. Many people who survive after being on mechanical
      ventilation for a prolonged time have significant issues with recovery and quality of life
      when discharged from the ICU. They are also more prone to depression, which increases
      patient suffering and the need for medical care, decreases quality of life, and is
      associated with increased mortality. Previous research indicates that antidepressant
      medications may improve quality of life and recovery in people who have had a heart attack,
      but that behavioral treatments are not effective in this case. Treating depression in ICU
      patients with respiratory failure has not been examined. In this study, antidepressant
      medications will be given to people who have been on mechanical ventilation in an ICU to
      determine the effectiveness of antidepressants in improving medical recovery and quality of
      life. Only a small number of participants will be enrolled in this trial to test the methods
      and theory; if it is successful, a larger trial will be conducted to determine whether these
      findings can be widely generalized.

      Participation in this study will last 8 weeks, with follow-up assessments lasting for 6
      months. Participants on a ventilation machine will be randomly assigned to receive either
      escitalopram, which is an FDA-approved antidepressant, or a placebo pill. A healthy
      surrogate may need to enroll participants in the study, because participants will begin
      treatment while in the ICU and may not be able to make an informed decision. The medication
      or placebo treatment will last for 2 months, continuing at the participant's home after
      discharge from the ICU. Dosage levels will begin at 10 mg per day and will be increased to
      20 mg per day for some participants after 3 to 5 weeks. Every 2 weeks, participants will
      complete questionnaires by phone or in person about their medical and psychological symptoms
      and about whether they are taking the study medication. At 8 weeks, participants will
      complete an in-person interview about depression symptoms, quality of life, and physical
      function. At 9 weeks, participants will complete a telephone interview about medication
      withdrawal. Finally, at 4 and 6 months, participants will complete interviews about
      depression and general health.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment Feasibility, Defined as the Number of Participants Recruited and Administered a Medication Dose Within 48 Hours of Mechanical Ventilation</measure>
    <time_frame>Measured within 2 days of participant recruitment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Planned Study Doses Actually Administered to Participants</measure>
    <time_frame>Measured after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Completed Interviews, Excluding Follow-ups</measure>
    <time_frame>Measured after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Reconsent Rate</measure>
    <time_frame>Measured after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Enrolled Compared to All Eligible Participants</measure>
    <time_frame>Measured 1 day after recruitment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate, Timing, and Tolerability of Medication Dose Escalation to 20 mg</measure>
    <time_frame>Measured after 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Off-protocol Antidepressant Use</measure>
    <time_frame>Measured after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success of Experimental Medication Blinding</measure>
    <time_frame>Measured after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression Severity, Measured by Center for Epidemiological Studies Depression Scale (CES-D), Between the Two Arms</measure>
    <time_frame>Measured after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression Severity, Measured by the 17-item Hamilton Depression Scale (HAM-D17)</measure>
    <time_frame>Measured after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression Severity, Measured by Montgomery Ã…sberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Measured after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Suicide Attempts and Suicidal Ideation</measure>
    <time_frame>Measured after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and Severity of Medication Withdrawal Symptoms</measure>
    <time_frame>Measured after 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Major Depressive Episodes and Incidences of Major Depressive Disorder, Measured by the Structured Clinical Interview for DSM-IV (SCID)</measure>
    <time_frame>Measured after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life, Measured by the 12-item Short Form Health Survey (SF-12)</measure>
    <time_frame>Measured after 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Adverse Events, Serious Adverse Events, and Deaths After the End of Treatment</measure>
    <time_frame>Measured after 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Burden, Defined as the Time Taken for Completion of the Study Questionnaires</measure>
    <time_frame>Measured after 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 8 weeks of escitalopram treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive 8 weeks of placebo pills.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>10 mg of escitalopram administered enterally with the option for dose escalation to 20 mg after 3 to 5 weeks if the medical condition is stable and no liver disease presents</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Lexapro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pills for 8 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly mechanically ventilated via an endotracheal tube

          -  Expected to remain intubated for at least 48 hours

          -  Fluent in English or Spanish

        Exclusion Criteria:

          -  Depression before admission to the ICU, as determined by a proxy interview

          -  Use of antidepressant medication within the last 2 weeks or a monoamine oxidase (MAO)
             inhibitor in the previous month

          -  History of suicide attempt

          -  Ventricular arrhythmias or a seizure requiring medication in the last 6 months

          -  History of retinal vascular proliferation or bleeding

          -  Migraine headaches treated with 5-HT1 agonists

          -  Organ transplant within the last 6 months

          -  Score of less than 4 on the Glasgow coma scale, in the absence of drug effects, for 2
             days

          -  Acute brain hemorrhage

          -  Increased intracranial pressure

          -  Active bleeding or less than 20,000 platelets/ul

          -  Expected prolonged inability to enterally administer escitalopram

          -  Residence more than 75 miles from study facility

          -  Serum sodium less than 125 mEq/l

          -  Hypersensitivity to citalopram or escitalopram

          -  Pregnant, breastfeeding, or possibly becoming pregnant in the next 3 months

          -  Undergoing life-support withdrawal or very low likelihood of 2-month survival

          -  Cognitive or communication impairment severe enough to preclude a conversation with
             an interviewer present before admission to ICU
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Weinert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 15, 2017</lastchanged_date>
  <firstreceived_date>March 30, 2009</firstreceived_date>
  <firstreceived_results_date>February 15, 2017</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Critical Illness</keyword>
  <keyword>Intensive Care Unit</keyword>
  <keyword>Acute Respiratory Failure</keyword>
  <keyword>Prolonged Mechanical Ventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Participants Will Receive 8 Weeks of Escitalopram Treatment.</title>
          <description>Participants will receive 8 weeks of escitalopram treatment.
Escitalopram: 10 mg of escitalopram administered enterally with the option for dose escalation to 20 mg after 3 to 5 weeks if the medical condition is stable and no liver disease presents</description>
        </group>
        <group group_id="P2">
          <title>Participants Will Receive 8 Weeks of Placebo Pills.</title>
          <description>Participants will receive 8 weeks of placebo pills.
Placebo: Placebo pills for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Participants Will Receive 8 Weeks of Escitalopram Treatment.</title>
          <description>Participants will receive 8 weeks of escitalopram treatment.
Escitalopram: 10 mg of escitalopram administered enterally with the option for dose escalation to 20 mg after 3 to 5 weeks if the medical condition is stable and no liver disease presents</description>
        </group>
        <group group_id="B2">
          <title>Participants Will Receive 8 Weeks of Placebo Pills.</title>
          <description>Participants will receive 8 weeks of placebo pills.
Placebo: Placebo pills for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Recruitment Feasibility, Defined as the Number of Participants Recruited and Administered a Medication Dose Within 48 Hours of Mechanical Ventilation</title>
        <time_frame>Measured within 2 days of participant recruitment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants Will Receive 8 Weeks of Escitalopram Treatment.</title>
            <description>Participants will receive 8 weeks of escitalopram treatment.
Escitalopram: 10 mg of escitalopram administered enterally with the option for dose escalation to 20 mg after 3 to 5 weeks if the medical condition is stable and no liver disease presents</description>
          </group>
          <group group_id="O2">
            <title>Participants Will Receive 8 Weeks of Placebo Pills.</title>
            <description>Participants will receive 8 weeks of placebo pills.
Placebo: Placebo pills for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Recruitment Feasibility, Defined as the Number of Participants Recruited and Administered a Medication Dose Within 48 Hours of Mechanical Ventilation</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Planned Study Doses Actually Administered to Participants</title>
        <time_frame>Measured after 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Completed Interviews, Excluding Follow-ups</title>
        <time_frame>Measured after 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Reconsent Rate</title>
        <time_frame>Measured after 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants Enrolled Compared to All Eligible Participants</title>
        <time_frame>Measured 1 day after recruitment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate, Timing, and Tolerability of Medication Dose Escalation to 20 mg</title>
        <time_frame>Measured after 5 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Off-protocol Antidepressant Use</title>
        <time_frame>Measured after 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Success of Experimental Medication Blinding</title>
        <time_frame>Measured after 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depression Severity, Measured by Center for Epidemiological Studies Depression Scale (CES-D), Between the Two Arms</title>
        <time_frame>Measured after 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depression Severity, Measured by the 17-item Hamilton Depression Scale (HAM-D17)</title>
        <time_frame>Measured after 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depression Severity, Measured by Montgomery Ã…sberg Depression Rating Scale (MADRS)</title>
        <time_frame>Measured after 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Suicide Attempts and Suicidal Ideation</title>
        <time_frame>Measured after 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Severity of Medication Withdrawal Symptoms</title>
        <time_frame>Measured after 9 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Major Depressive Episodes and Incidences of Major Depressive Disorder, Measured by the Structured Clinical Interview for DSM-IV (SCID)</title>
        <time_frame>Measured after 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life, Measured by the 12-item Short Form Health Survey (SF-12)</title>
        <time_frame>Measured after 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of Adverse Events, Serious Adverse Events, and Deaths After the End of Treatment</title>
        <time_frame>Measured after 12 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Burden, Defined as the Time Taken for Completion of the Study Questionnaires</title>
        <time_frame>Measured after 12 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Participants Will Receive 8 Weeks of Escitalopram Treatment.</title>
          <description>Participants will receive 8 weeks of escitalopram treatment.
Escitalopram: 10 mg of escitalopram administered enterally with the option for dose escalation to 20 mg after 3 to 5 weeks if the medical condition is stable and no liver disease presents</description>
        </group>
        <group group_id="E2">
          <title>Participants Will Receive 8 Weeks of Placebo Pills.</title>
          <description>Participants will receive 8 weeks of placebo pills.
Placebo: Placebo pills for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Eye/Ear</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Medra">GI</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title vocab="Medra">Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous Sytem</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genital/Urinary</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Craig Weinert MD</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-624-0999</phone>
      <email>weine006@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
